According to a Securities and Exchange Commission filing, start-up biotech Semnur Pharmaceuticals has raised $6 million of a projected $30-million funding round that the company will reportedly use to advance its non-opioid injectable drug treatment for lower back pain. According to a news source, phase 2 clinical trials for the drug are expected to begin in the third quarter of 2014, and the company plans to either develop and commercialize the product on its own or work with partners. See MedCityNews.com, August 21, 2013.